New drug G1090N tested in healthy volunteers for first time

NCT ID NCT07110441

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety and how the body handles a new drug called G1090N in 52 healthy adults. Participants received single or multiple doses up to 1200 mg. The goal was to measure drug levels in blood and urine, and check for side effects. This is a first step before testing the drug in people with acute-on-chronic liver failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

G1090N

What this could lead to

If successful, this could support further testing of G1090N as a potential treatment for acute-on-chronic liver failure.

What could go wrong

This is a very early Phase 1 study in healthy volunteers, not patients. It only measures safety and drug processing, not whether the drug works for liver failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States